UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012965
Receipt number R000015157
Scientific Title Measurement of plasma concentrations of yokukansan in form of suppository to healthy Japanese volunteers
Date of disclosure of the study information 2014/01/26
Last modified on 2015/08/27 16:02:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Measurement of plasma concentrations of yokukansan in form of suppository to healthy Japanese volunteers

Acronym

Pharmacokinetics of yokukansan component in form of suppository to healthy Japanese volunteers

Scientific Title

Measurement of plasma concentrations of yokukansan in form of suppository to healthy Japanese volunteers

Scientific Title:Acronym

Pharmacokinetics of yokukansan component in form of suppository to healthy Japanese volunteers

Region

Japan


Condition

Condition

healthy Japanese volunteers

Classification by specialty

Anesthesiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the pharmacokinetics of yokukansan component in the form of suppository, we measure the plasma concentration of yokukansan alkaloid such as hirsuteine or geissoschizine methyl ether after administration. In addition, we measure the concentration after oral administration of yokukansan to investigate the difference of pharmacokinetics due to administration route.

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Time course of plasma levels of hirsuteine and geissoschizine methylether after enteric administration of yokukansan

Key secondary outcomes

Time course of plasma levels of hirsuteine and geissoschizine methylether after oral administration of yokukansan


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Blood sampling time: before, and 0.5, 1, 2, and 4 hour after the enteric administration with 7.5g yokukansan
Blood sampling time: before, and 0.5, 1, 2, and 4 hour after the oral administration with 7.5g yokukansan

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >=

Gender

Male and Female

Key inclusion criteria

a) Healthy volunteers
b) Agreement to sign an informed consent

Key exclusion criteria

a) Patients who are allergic to medicines, or foods related to the test material of this trial
b) Pregnant women, lactating women, or women who want to get pregnant during the trial period
c) Patients who are enrolled in the other clinical trials before the agreement for the participation to this trial
d) Patients who are judged not suitable to participate in this trial by physician.

Target sample size

5


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ryoko Kawahara

Organization

Nissay Hospital

Division name

Anesthesiology and Palliative care

Zip code


Address

6-3-8, Itachibori, Nishi-ku, Osaka, 550-0012

TEL

06-6543-3581

Email

kawahara.ryoko@nissay-hp.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ryoko Kawahara

Organization

Nissay Hospital

Division name

Anesthesiology and Palliative care

Zip code


Address

6-3-8, Itachibori, Nishi-ku, Osaka, 550-0012

TEL

06-6543-3581

Homepage URL


Email

kawahara.ryoko@nissay-hp.or.jp


Sponsor or person

Institute

Nissay Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 01 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2013 Year 12 Month 05 Day

Date of IRB


Anticipated trial start date

2014 Year 01 Month 26 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 01 Month 26 Day

Last modified on

2015 Year 08 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015157


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name